Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials
Clicks: 201
ID: 113830
2012
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
201 views
40 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #163 of 1,084 articles by views in clinical infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,084 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract. Two recently completed phase 3 trials (003 and 004) showed fidaxomicin to be noninferior to vancomycin for curing Clostridium difficile infection (CD
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (20 words).
Try re-searching for a better abstract.
| Reference Key |
w.2012clinicalfidaxomicin
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Crook, Derrick W.;Walker, A. Sarah;Kean, Yin;Weiss, Karl;Cornely, Oliver A.;Miller, Mark A.;Esposito, Roberto;Louie, Thomas J.;Stoesser, Nicole E.;Young, Bernadette C.;Angus, Brian J.;Gorbach, Sherwood L.;Peto, Timothy E. A.;for the Study 003/004 Teams; |
| Journal | clinical infectious diseases |
| Year | 2012 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.